N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss encouraging data from its oncology research. Nigel describes the behavior of Nuvec, explains why now a focus on oncology, work
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided details of its work plan following the encouraging data
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a strategic update following data from its proof-of-concept programmes
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that further to the Company’s announcement dated 11 February
N4 Pharma’s Nigel Theobald discusses highlights from their interim results, key findings in the optimisation work, progress of the two MTA’s, patents and what investors can expect in the next 6 months in this exclusive interview with DirectorsTalk.
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss interim results for the six months ended 30 June 2021. Nigel talks us through the highlights, talks about
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its current in vivo work streams due
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
